EGFR and hepatocellular carcinoma: We treated TKO HCC cells and organoids derived from primary TKO HCC tumors with Erlotinib® (EGFR inhibitor49), Afatinib® (EGFR family inhibitor50), and Sorafenib® (a multi-kinase inhibitor used as a control51).